These last applications are addressed honestly with patients as preliminary rather than established clinical indications
Cost Reduction: SHIRATAMA intravenous therapy requires clinical procedures, which can be expensive for regular treatments
Reports from Q4 2003 to Q1 2024 were analyzed using the OpenVigil 2.1 platform to identify male patients experiencing orgasmic dysfunction, erectile dysfunction, or decreased libido linked to GLP-1 receptor agonists (tirzepatide, semaglutide, dulaglutide, exenatide, lixisenatide, and liraglutide)
Low ascorbic acid in the vtc-1 mutant of Arabidopsis is associated with decreased growth and intracellular redistribution of the antioxidant system
Valid for 365 days
Outcomes were similar to the other STEP trials, with the co-primary outcome being percentage change from baseline in body weight and the percentage of patients achieving a 5% or greater weight reduction